Purpose-built economic zone enables life sciences companies to manage research from one strategic location
As demand for domestic production of pharmaceuticals increases across the GCC region, Khalifa Economic Zones Abu Dhabi – KEZAD Group showcased the competitive advantage Abu Dhabi offers to researchers, manufacturers and distributors looking at Arab Health 2023.
KEZAD already hosts many pharmaceutical manufacturers, life science businesses, laboratories, and supporting services, including several leading organisations such as Hope Consortium, and Pharmatrade, including the G42, which announced the development of one of the largest vaccine production facilities in KEZAD last year.
Currently spread across 1.6sqkm and supported by multi-modal transport links via land, sea, air, and upcoming rail, KEZAD’s healthcare and life science ecosystem offers fast set-up times for companies through a range of solutions including serviced land plots and diverse built-to-suit facilities, a press communique indicated.
“As a leading facilitator of industry and manufacturing, KEZAD Group currently supports the operations of leading healthcare businesses via its Life Sciences Hub,” remarked Mohamed Al Khadar Al Ahmad, CEO, Khalifa Economic Zones Abu Dhabi -KEZAD Group.
In addition to critical infrastructure, such as advanced cold-chain storage and blockchain management for safe and secure vaccine distribution, KEZAD Group offers unrivalled multimodal connectivity, linking healthcare businesses to global markets, with access to approximately 4.5 billion people worldwide, the press statement concluded.